Previous close | 39.40 |
Open | 37.30 |
Bid | 35.50 |
Ask | 36.70 |
Strike | 755.00 |
Expiry date | 2023-05-19 |
Day's range | 37.30 - 37.30 |
Contract range | N/A |
Volume | |
Open interest | 26 |
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.
In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day.